Ketorolaco [Spanish] en es it fr

Ketorolaco [Spanish] Brand names, Ketorolaco [Spanish] Analogs

Ketorolaco [Spanish] Brand Names Mixture

  • No information avaliable

Ketorolaco [Spanish] Chemical_Formula


Ketorolaco [Spanish] RX_link

Ketorolaco [Spanish] fda sheet

Ketorolaco_[Spanish] FDA

Ketorolaco [Spanish] msds (material safety sheet)

Ketorolaco [Spanish] Synthesis Reference

No information avaliable

Ketorolaco [Spanish] Molecular Weight

285.303 g/mol

Ketorolaco [Spanish] Melting Point

184-185 oC

Ketorolaco [Spanish] H2O Solubility

No information avaliable

Ketorolaco [Spanish] State


Ketorolaco [Spanish] LogP


Ketorolaco [Spanish] Dosage Forms


Ketorolaco [Spanish] Indication

For the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. Also for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Ketorolaco [Spanish] Pharmacology

Letrozole is an aromatase inhibitor used in the treatment of breast cancer. Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization. As breast tissue is stimulated by estrogens, decreasing their production is a way of suppressing recurrence of the breast tumor tissue.

Ketorolaco [Spanish] Absorption

Rapidly and completely absorbed. Absorption is not affected by food.

Ketorolaco [Spanish] side effects and Toxicity

No information avaliable

Ketorolaco [Spanish] Patient Information

No information avaliable

Ketorolaco [Spanish] Organisms Affected

Humans and other mammals